Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
Yongchang Zhang, Zhe Huang, Liang Zeng, Xiangyu Zhang, Yizhi Li, Qinqin Xu, Haiyan Yang, Analyn Lizaso, C. Xu, Jun Liu, Wenxian Wang, Zhengbo Song, Sai‐Hong Ignatius Ou, Nong Yang
Abstract
This retrospective study investigated the association between the pattern of disease progression and molecular mechanism of acquired resistance in a large cohort of 49 patients with ROS1-rearranged advanced non-small-cell lung cancer treated with first-line crizotinib. We found that treatment-emergent ROS1 point mutations were the major molecular mechanism of crizotinib resistance, particularly for patients who developed extracranial-only disease progression. Our findings highlight the importance of rebiopsy and gene testing for subsequent-line therapeutic management.